

Office Guide for XDEMZY[®] Prescription Access

1 Diagnose:

For access to XDEMZY, a prescriber must diagnose and include diagnosis on the Rx:

- For patients diagnosed with *Demodex* blepharitis, write *Demodex* blepharitis in the prescription notes section
- List ICD-10 Codes of H01.00_ and B88.0 or other appropriate codes in the prescription diagnosis field and/or prescription notes section.¹ For a **full list of codes**, please see back page.

2 ePrescribe: ePrescribe XDEMZY to any one of the following 4 pharmacies (Prescription Form is available via xdemvyhcp.com for faxing):

<p>AllianceRx Walgreens Pharmacy Phone: 1-800-424-9002 Fax: 1-800-874-9179 Address: 41460 Haggerty Circle South Canton, MI 48188 NPI #: 1942303110</p>	<p>BlinkRx Phone: 844-926-2480 Fax: 1-866-585-4631 Address: 4696 West Overland Road, Suite 274 Boise, ID 83705 NPI #: 1891461885</p>
<p>Carepoint Pharmacy Phone: 855-237-9112 Fax: 1-855-237-9113 Address: 9 E. Commerce Drive Schaumburg, IL 60173 NPI #: 1598013864</p>	<p>CVS Specialty Pharmacy (2 locations) Phone: 1-800-237-2767 Fax: 1-800-323-2445 Address 1: 800 Biermann Court Suite B Mount Prospect, IL 60056 NPI #: 1134100134 Address 2: 105 Mall Boulevard Monroeville, PA 15146 NPI #: 1043382302</p>

Accurate Patient Information: Please include patient DOB, contact phone number, prescription plan name, and pharmacy member ID

- If a PA is needed, the pharmacy you selected will initiate the PA form with CoverMyMeds
- Office must complete, sign, and submit PA

Prescription Information: XDEMZY (lotilaner ophthalmic solution) 0.25%

- Quantity: 10 mL fill in a 11mL container
- Sig: Instill one drop in each eye twice daily (approximately 12 hours apart) for 6 weeks

3 Set Patient Expectations:

IMPORTANT: Office informs patients that the pharmacy will be contacting them. Share the details so the patient knows what to expect:

- Pharmacy will call from an unknown number, so please advise patient to answer the call
- If a copay is needed, pharmacy will obtain payment from patient
- Pharmacy will work with patient to arrange delivery

Indication and Usage

XDEMZY[®] is indicated for the treatment of *Demodex* blepharitis.

Important Safety Information

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Please see additional Important Safety Information on page 2. Please [click](#) for full Prescribing Information.

**Should you have access challenges and/or wish to get additional support and information,
please reach out to your Tarsus Support Team:**

Name:	
Title:	
Phone Number:	
Email:	

Tarsus Connect™

We make XDEMZY® access easy

For XDEMZY access support, contact Tarsus Connect at [xdemvy.com](https://www.xdemvy.com) or 1-866-846-3092

For your patients with *Demodex* blepharitis, it is important to indicate the diagnosis and related ICD-10 diagnosis code(s), for example¹:

- **B88.0 (Other acariasis)**
- **H01.00 (Unspecified blepharitis)**
 - H01.001: Unspecified blepharitis right upper eyelid
 - H01.002: Unspecified blepharitis right lower eyelid
 - H01.003: Unspecified blepharitis right eye, unspecified eyelid
 - H01.004: Unspecified blepharitis left upper eyelid
 - H01.005: Unspecified blepharitis left lower eyelid
 - H01.006: Unspecified blepharitis left eye, unspecified eyelid
 - H01.009: Unspecified blepharitis unspecified eye, unspecified eyelid
 - H01.00A: Unspecified blepharitis right eye, upper and lower eyelids
 - H01.00B: Unspecified blepharitis left eye, upper and lower eyelids¹

Important Safety Information (continued)

Use with Contact Lenses: XDEMZY® contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMZY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMZY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please [click](#) for full Prescribing Information.

Reference: 1. Centers for Medicare & Medicaid Services. 2023 ICD-10-CM: April 1, 2023 UPDATE. Accessed July 10, 2023. <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm>